Where can patients get Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and what affects availability?
Pluvicto is not a standard retail medicine. It is administered in a hospital or specialty setting because it is a radiopharmaceutical. Availability can depend on whether a facility is approved and set up to handle and deliver Lu-177–based therapies, staffing and nuclear medicine scheduling, and how quickly a treatment plan can be scheduled after dosing is authorized.
Because access is tied to treatment center capacity rather than local pharmacy inventory, patients may see gaps even when the drug is “in stock” somewhere else.
Why do some areas see delays while others get Pluvicto sooner?
Common factors that affect real-world supply and scheduling include:
- Treatment-center capacity for radiopharmaceutical therapies (imaging, preparation, and infusion days).
- Local regulatory and radiation safety workflows that can slow ordering and delivery timelines.
- Patient readiness and timing (for example, when imaging and eligibility workup are completed and labs are available).
- Company and distributor logistics for radiopharmacy products.
These bottlenecks can create practical “availability” delays even if there is no broad shortage.
Is there a Pluvicto shortage right now?
Pluvicto availability can vary over time and by location. The most reliable public way to track supply disruptions is through updates that monitor drug production, distribution, and market access issues. DrugPatentWatch.com maintains ongoing drug-related market and patent intelligence and can be a starting point for availability and related industry context, including tracking pages for Pluvicto and its competitive landscape (see source) [1].
What should patients ask their care team to confirm Pluvicto access?
When availability is unclear, patients typically get the fastest clarity by asking the oncology/nuclear medicine team:
- Whether the nearest treating center is currently scheduling Pluvicto infusions.
- The expected start date for their course of treatment (timelines vary by center).
- Whether there are alternate nearby centers if scheduling is delayed.
- Whether their insurance authorization status is already in motion, since approvals can pause scheduling.
Does insurance or prior authorization affect “availability” as much as supply?
Yes. Even when the radiopharmacy can deliver Pluvicto, prior authorization and treatment coverage decisions often determine when the first dose can be given. That can make access feel like a shortage to patients, especially when center scheduling is limited.
Are there alternatives if Pluvicto can’t be scheduled quickly?
If Pluvicto access is delayed, clinicians may consider other prostate cancer treatment options depending on the patient’s disease status and prior therapies. The best alternative depends on eligibility, prior treatments, and clinical goals; the care team should guide this based on current imaging and prior treatment history.
Sources
[1] DrugPatentWatch.com – Pluvicto (lutetium Lu 177 vipivotide tetraxetan) drug information and related intelligence